TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Caroline Piatek, MD
Irina Murakhovskaya, MD
Thomas Kipps, MD, PhD
Thomas Kipps, MD, PhD
William Wierda, MD, PhD
Talha Munir, PhD
Thomas Kipps, MD, PhD
William Wierda, MD, PhD